| Ulcerative Colitis
Skyrizi vs Uceris
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Skyrizi vs Uceris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUceris has a higher rate of injection site reactions vs Skyrizi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uceris but not Skyrizi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Skyrizi
Uceris
At A Glance
SC injection
Every 8-12 weeks
IL-23 antagonist
Rectal foam
Twice daily, then once daily
Glucocorticosteroid
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
- Ulcerative Colitis
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter.
Crohn Disease Induction: 600 mg IV infusion over at least 1 hour at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Ulcerative Colitis Induction: 1,200 mg IV infusion over at least 2 hours at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Ulcerative Colitis 1 metered dose administered rectally twice daily for 2 weeks, followed by 1 metered dose administered rectally once daily for 4 weeks.
Contraindications
- Previous serious hypersensitivity reaction to risankizumab-rzaa or any excipient
- History of known hypersensitivity to budesonide or any ingredient of UCERIS rectal foam, including anaphylaxis
Adverse Reactions
Most common Upper respiratory infections, headache, fatigue, injection site reactions, tinea infections, arthralgia, pyrexia, rash
Serious Cellulitis, osteomyelitis, sepsis, herpes zoster, pneumonia
Postmarketing Eczema, rash
Most common (>=2%) Decreased blood cortisol, adrenal insufficiency, nausea
Serious Hypercorticism and adrenal axis suppression, steroid withdrawal symptoms, increased susceptibility to infection, other glucocorticosteroid effects
Postmarketing Hypertension, pancreatitis, pyrexia, peripheral edema, anaphylactic reactions, dizziness, benign intracranial hypertension, mood swings, pruritus, maculopapular rash, allergic dermatitis
Pharmacology
Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine, inhibiting its interaction with the IL-23 receptor and suppressing the release of pro-inflammatory cytokines and chemokines.
Budesonide is a synthetic non-halogenated glucocorticosteroid that exerts local anti-inflammatory activity via glucocorticosteroid receptor binding; it undergoes extensive first-pass hepatic metabolism via CYP3A4, resulting in low systemic bioavailability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Skyrizi
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Uceris
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Skyrizi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Uceris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Skyrizi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Uceris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Uceris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SkyriziView full Skyrizi profile
UcerisView full Uceris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.